ArticleRMD open2025
Intra-articular sustained-release colchicine is efficacious in an inflammatory arthritis rat model.
Article in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultrasound-responsive hydrogel microcarriers co-loading dexamethasone and urate oxidase for localized gout management.Frontiers in chemistry · 2026Article
- Establishment and phenotypic characterization of a rat model with a clinically relevant phenotype for chronic gouty arthritis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGout is a common disease causing excruciatingly painful and disabling flares. Although currently approved treatments for gout flares are generally effective, their use is restricted in many patients who present contraindications. There is a clear unmet need for treatments, with a rapid onset of action and a good safety profile. This study evaluates the efficacy of intra-articular (IA) colchicine (COL)-loaded microspheres enabling sustained-release colchicine (SR-COL), and of a combination of SR-COL with an anaesthetic (Ropivacaine HCl, ROPI) (PKM-01) in a rat model of acute inflammatory arthritis.
methodsPKM-01 combines ROPI with SR-COL, prepared using a polylactic-co-glycolic acid matrix polymer. A model of IA carrageenan (CAR)-induced arthritis in knees or ankles was adapted for this study. Treatments (phosphate buffer saline, dexamethasone, SR-COL, ROPI or PKM-01) were administered intra-articularly immediately following the CAR injection. Pain was assessed using Von Frey filaments or weight-bearing tests. Histological scores assessed joint inflammation and destruction.
resultsAll animals experienced acute painful and destructive arthritis following CAR injection. ROPI effectively alleviated pain but had no significant impact on inflammation or joint destruction. SR-COL demonstrated efficacy in reducing pain, inflammation and joint destruction across all parameters. PKM-01 provided a strong and rapid analgesic effect and exhibited anti-inflammatory properties, as evidenced by histological analysis of joint inflammation and destruction. Blood levels of COL after ankle injections were significantly below toxicity thresholds.
conclusionsThese data indicate that PKM-01 may serve as an effective and safe treatment option for acute inflammatory arthritis. A clinical trial is planned in gout flare patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.